

Chen Chen

Special Counsel



chen.chen@cooley.com

Life Sciences Corporate Partnering and Licensing
Emerging Companies

+1 650 843 5592

Life Sciences
Venture Capital

Palo Alto

Chen represents public and private life sciences companies in strategic licensing and collaboration transactions, including discovery and research collaborations, option agreements, co-development and co-commercialization arrangements, and territory-specific agreements. She is experienced in cross-border transactions involving inbound or outbound licenses or joint ventures. She also counsels life sciences clients on day-to-day operational matters such as vendor services, manufacturing and supply, sponsored research, and clinical trials.

Chen's recent matters include representing:

- Merus in its research collaboration with Biohaven to co-develop three novel bispecific antibody-drug conjugates (ADCs) leveraging Merus' leading antibody technology platform and Biohaven's ADC conjugation and payload platform technologies (2025)
- Avenzo Therapeutics in its agreement with Duality Biotherapeutics to obtain global rights (excluding Greater China) for DB-1418, an epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 3 (HER3) bispecific ADC (2025)
- Kura Oncology in its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, with profit-sharing in the US (2024)
- Radionetics Oncology in its strategic collaboration with Eli Lilly to develop Radionetics' proprietary G protein-coupled receptor-targeting small molecule radiopharmaceuticals, with an option for Lilly to acquire Radionetics upon conclusion of an exercise period (2024)
- OrbiMed in a newly formed company transaction (Belenos Biosciences) with Keymed Biosciences for exclusive global rights (excluding Greater China) for CM512 and CM536, Keymed's proprietary bispecific antibodies (2024)
- SystImmune in its global collaboration with Bristol Myers Squibb to develop and commercialize BL-B01D1, SystImmune's novel EGFR/HER3 bispecific ADC, with profit-sharing in the US (2023)
- MediLink Therapeutics in its strategic collaboration with BioNTech to license MediLink's proprietary ADC directed to HER3, with MediLink retaining rights in Greater China (2023)
- Genomatica in its joint venture with Unilever to commercialize and scale plant-based alternatives to feedstocks like palm oil and fossil fuels to make key ingredients used in everyday cleaning and personal care products (2022)

Education

Harvard Law School

JD cum laude, 2017

Stanford University

PhD , 2014

Wesleyan College

BA summa cum laude, 2009

Admissions & Credentials

California